Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Jaktinib in ruxolitinib-relapsed/refractory myelofibrosis
NCT04851535Phase 2Completed
- Sponsor
- Zelgen
- Start
- Jul 2021
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of jaktinib in myelofibrosis (MF), sponsored by Zelgen. Started Jul 2021; status: completed.
02
Drugs
jaktinib
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT04851535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04851535.